Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ALC · NYSE · United States · Ophthalmic Goods
In shortALCON INC is profitable, generates cash and carries moderate debt, with revenue growing (+4.9% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 13.1% | 60/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 9.4% | 58/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 4.5% | 22/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 4.3% | 29/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.12× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.21× | 99/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 2.36× | 47/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 6.67× | 49/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 16.6% | 86/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.76× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 7.1% | 85/100 |
| Operating margin volatility | 3.2% | 80/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 6.1% | 50/100 |
|---|---|---|
| EPS growth, 3-year average | 42.8% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 8,291 | 8,717 | 9,455 | 9,911 | 10,401 |
| Cost of revenue | 3,577 | 3,910 | 4,141 | 4,328 | 4,592 |
| Gross profit | 4,652 | 4,748 | 5,247 | 5,512 | 5,745 |
| Research & development | 842 | 702 | 828 | 876 | 990 |
| Selling, general & admin | 3,076 | 3,068 | 3,209 | 3,250 | 3,449 |
| Operating income | 580 | 672 | 1,039 | 1,413 | 1,360 |
| Interest expense | 120 | 134 | 189 | 192 | 204 |
| Pre-tax income | 418 | 463 | 832 | 1,256 | 1,160 |
| Income tax | 42 | 128 | (142) | 238 | 180 |
| Net income | 376 | 335 | 974 | 1,018 | 980 |
| Diluted EPS | $0.76 | $0.68 | $1.96 | $2.05 | $1.98 |
| Diluted shares (millions) | 493 | 494 | 497 | 498 | 496 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
Not computed: a required balance-sheet item is missing.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Feb 24, 2026